Condition: RSV Infection · RSV · Respiratory Syncytial Virus (RSV) · Sponsor: Enanta Pharmaceuticals, Inc
Zelicapavir is a novel, orally administered, nonfusion replication inhibitor of RSV. It is being investigated in this Phase 2 study (EDP 938-203) as a potential treatment for RSV infection in both hospitalized and non-hospitalized children aged ≥28 days to ≤36 months who present with symptomatic RSV infection.
This description comes directly from the study's public registry record.
Enanta Pharmaceuticals, Inc · 617 607-0800 · charris@enanta.com
Always discuss trial participation with your own doctor first.
| Center of Excellence for Pediatric Infectious Diseases and Vaccines Faculty of Medicine, Chulalongkorn University (CE-PID) | Bangkok, Thailand | Recruiting |
| Nakornping Hospital | Chiang Mai, Thailand | Recruiting |
| Maharaj Nakorn Chiang Mai Hospital | Chiang Mai, Thailand | Recruiting |
| Chiangrai Prachanukroh Hospital | Chiang Rai, Thailand | Recruiting |
| Khon Kaen Hospital | Khon Kaen, Thailand | Recruiting |
| Lampang Hospital | Lampang, Thailand | Recruiting |
| Lamphun Hospital | Lamphun, Thailand | Recruiting |
| Maha Sarakham Hospital | Maha Sarakham, Thailand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07482657